Publications by authors named "R Hills"
Purpose: To evaluate the survival benefit of chemotherapy intensification in older patients with AML who have not achieved a measurable residual disease (MRD)-negative remission.
Methods: Five hundred twenty-three patients with AML (median age, 67 years; range, 51-79) without a flow cytometric MRD-negative remission response after a first course of daunorubicin and AraC (DA; including 165 not in remission) were randomly assigned between up to two further courses of DA or intensified chemotherapy-either fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin (FLAG-Ida) or DA with cladribine (DAC).
Results: Overall survival (OS) was not improved in the intensification arms (DAC DA: hazard ratio [HR], 0.
Background: Patients with kidney failure often lack robust evidence because they are excluded from randomized trials. Trial emulation provides an alternative approach to derive treatment effect estimates when randomized trials cannot be conducted. Critical questions about the comparative efficacy and safety of interventions in kidney failure are now being answered using this approach or parts of it.
View Article and Find Full Text PDFArticle Synopsis
- Acute myeloid leukemia (AML) often involves deletions of chromosome 7, which are linked to poor patient outcomes, but the full impact of other genetic changes related to this is not well understood.
- Researchers analyzed genetic alterations in 519 AML patients, using whole-exome sequencing and a specialized gene panel, finding that mutations in TP53, which occurred in 33% of cases, were among the most common.
- The study identified specific genes, like TP53 and PTPN11, that have a significant negative effect on overall and relapse-free survival, highlighting the complex relationship between chromosome 7 abnormalities and patient prognosis in AML.
Article Synopsis
- High densities of CD3 and CD8 T-cells in colorectal cancer are linked to better patient prognosis, but their effectiveness in predicting chemotherapy benefits remains unclear.
- A study analyzed tumor tissue from 868 colorectal cancer patients and found that those with high-risk CD3/CD8 cell densities had recurrence rates twice as high as low-risk patients, consistently observed in both training and validation sets.
- The findings suggest that while high-risk patients experience more recurrences, chemotherapy provides similar proportional benefits across both high- and low-risk groups, leading to updated treatment recommendations based on the CD3/CD8 cell density scores.
Defending against future pandemics requires vaccine platforms that protect across a range of related pathogens. Nanoscale patterning can be used to address this issue. Here, we produce quartets of linked receptor-binding domains (RBDs) from a panel of SARS-like betacoronaviruses, coupled to a computationally designed nanocage through SpyTag/SpyCatcher links.
View Article and Find Full Text PDF